Synairgen Share Discussion Threads

[nobbygnome] 19/4/2020 07:12

A cheery optimistic thought for a Sunday morning!

If and when a positive result on SNG001 is announced, it will be the first or certainly one of the first placebo controlled double blind trials to be announced using a drug to fight Covid 19. That means this will be global news and will be talked about absolutely everywhere. For example it will make the 8 o'clock BBC news that morning I suspect. Indeed there may well be a global stock market rally on the back of the result because of the massive potential for the fight against Covid 19. Just think about the implications of all that on a potential valuation of the company!

Just IMHO and of course we need to get a positive result first which may or may not happen....

[imjustdandy] 19/4/2020 07:01

More news on the deal to be announced tomorrow. We will definitely qualify. https://twitter.com/markkleinmansky/status/1251608431007608840?s=21

[imjustdandy] 19/4/2020 06:59

We could be in for another £5m pounds tomorrow. We raised £14m and this scheme is matched up to £5m . Holy smoke - here we go. https://twitter.com/markkleinmansky/status/1251606658075295744?s=21

[jev1] 18/4/2020 21:01

Don't be so modest Bob.

You know it's at least fifteen ! :o)

[amaretto1] 18/4/2020 20:01

What's the possible upside here ?

[nobbygnome] 18/4/2020 18:48

Some interesting links. The one about analysing the sputum is the data presented by SNG via a poster at a conference last year from the first stage of the COPD study. It is is good data but not conclusive. The others all stress the importance of interferon in the anti viral response which is reassuring.

Still no guarantee of a positive result but you are correct in that I am very optimistic!

[talk2dubya] 18/4/2020 18:48

‘ The evidence is quite overwhelming and we've the golden patent’

Spot on.

[likya123] 18/4/2020 18:14

Think you're not joining the massive dots in that Interferon beta-1 is the perfect drug as the previous studies have shown (ex vivo, using lung tissue) is that Covid-19 (=SARS-CoV-2) induces a much lower interferon response compared with SARS-Cov, even though the virus replicates more rapidly.

Nobby will not like this but from my research I believe inhaled sng001 will show clinically statistically significant positive results in the management of covid-19.

The evidence is quite overwhelming and we've the golden patent for the inhaled administration of this wonder drug!

It is of no coincidence that the NIHR have prioritised this trial as "urgent" just over 2 weeks after the dosing of our first patient.


Two more links from lse board just now, I understand that interferon alpha 1b below is not considered as effective as interferon beta-1 which is yet another huge plus for what I believe will be very positive results from our trial..






I'm no specialist in this area but Nobby is and I believe that although he is correctly ultra conservative, deep down he also expects fireworks from the trial results.

[ambyth] 18/4/2020 18:11

Likya123 > Just a note of caution to your high enthusiasm, that study is for COPD, rather than Covid-19. I definitely think there's good value here and am strongly invested, but nothing is proven until its proven, hence the double blind trial...

[likya123] 18/4/2020 17:59

And yet more evidence that we're on to a sure winner.
I'm full to the brim with Synairgen but curently looking for more cash to add as many as posible on Monday.

Courtesy of lse board..







So, basically through research, the whole world knows that it Interferon Beta via inhaled nebuliser now improves patients, in evidenced trials. Synairgen has the global patents -happy days.

[d1nga] 18/4/2020 17:07

Good find likya and strengthens the case for inhaled interferons.

[likya123] 18/4/2020 16:55

Nobby, a little technical for me but again seems to be massively positive for our upcoming trial results.
Please have a read and kindly share your thoughts..

Pessonally I'll be shocked if our trial results don't show clinically significant positive results.

Courtesy of SGD27 lse board..

This is a week or two old, but I don't recall seeing it posted - apols if it was. It's quite technical, so here's my (very much non-expert) summary :

What they've shown (ex vivo, using lung tissue) is that Covid-19 (=SARS-CoV-2) induces a much lower interferon response compared with SARS-Cov, even though the virus replicates more rapidly.

We already know that coronaviruses have this apparent ability to suppress the interferon response (as Richard Marsden has been telling us, e.g. in the recent Proactive interview ~3 minutes in). But this study appears to be showing that Covid-19 is especially good at it!

[talk2dubya] 18/4/2020 15:29

hxxps://www.pharmaceutical-journal.com/news-and-analysis/features/the-hunt-for-an-effective-treatment-for-covid-19/20207883.article?firstPass=false

The first table in the attached link makes interesting reading.

There are two ways of attacking the problem. “In an infection, you’re basically at war — it’s your immune system versus the virus,” Heneghan says. “If your immune system is functioning OK, at some point it will win.” If it is not, you either have to reduce its workload by killing off the virus or give it a boost.

This is where interferon beta — a protein that is produced by the body as a defensive response to viruses — comes in. Several trials are examining its potential in helping patients with severe COVID-19, including a placebo-controlled trial of an inhaled interferon beta formulation produced by Synairgen, led by Tom Wilkinson at the University of Southampton, and which Hall is also involved in.

Some people will not produce adequate amounts of interferon beta, says Hall, “either because we’ve got other diseases or our immune response is less strong, as tends to happen as we get older.”

[bountyhunter] 18/4/2020 15:21

OXB will be manufacturing if the Oxford vaccine clinical trial goes well. They already have manufacturing facilities which may be directed towards this if the vaccine is successful with scientists optimistic. There are dozens of Covid-19 vaccines in development around the world but the Oxford one sounds to be one of the most promising and ahead of the crowd with anticipated timescales.

[talk2dubya] 18/4/2020 15:12

Interesting that for this new vaccine trial by Oxford Uni they the lead has said this:

Sir John continued: 'The crucial thing is you have to do a proper trial because safety is really important for these things.

'But if we can see evidence of a strong immune response by the middle or the end of May, then I think the game is on.
'And they may well get across the finish line by mid-August. Then, of course, there is the massive issue of how you manufacture at scale many billions of doses.'

I am wondering if we are at the game on stage already?

[pdt] 18/4/2020 14:40

SNG also has a 17% stake in a LOXL2 inhibitor being developed by Pharmaxis. News of a partner could come any day and the upfront could be in the region of $50 million (SNG get 17% of that)

So it is encouraging to see a study (in a murine model) that LOXL2 inhibition not only stops liver fibrosis but helps with it's repair.

"LOXL2 Inhibition Paves the Way for Macrophage-Mediated Collagen Degradation in Liver Fibrosis"



Any thoughts Nobby?

[nobbygnome] 18/4/2020 13:24

Well my oft quoted thoughts are that injected interferon beta won't work because you won't get a high enough level to the lungs. However, the general positive vibe about interferon has got to be a good sign......but not a guarantee.

[talk2dubya] 18/4/2020 13:20

Nobby what do you think the significance of Merck donating 240k units of Interfon to the WHO are on Synairgen prospects?

hxxps://www.ipgroupplc.com/media/portfolio-news/2009/2009-09-04b

[imjustdandy] 18/4/2020 13:12

That are manufacturing GBP4M of SNG001 so must be v confident

Use of proceeds


COVID-19 clinical trial activity GBP7m
Manufacture of SNG001 drug product and other supply GBP4m
chain considerations
Strengthened balance sheet for potential partnering GBP3m
discussions with regards to the COVID-19, future
pandemic preparedness, and the COPD opportunity,
working capital and fees

[nobbygnome] 18/4/2020 13:12

Yes not impossible that they will announce an update on recruitment but definitely not on efficacy.

[bountyhunter] 18/4/2020 13:05

"The limiting factor will be the paperwork and time to get them on the trial not the number of patients."

Yes that's exactly what I was thinking.
An update from the company on numbers recruited to date would be useful information as obviously they can't reveal any information on how it's going clinically at this time.
(Yes I know it's double blind).

[talk2dubya] 18/4/2020 12:33

Apologies if already posted:

[likya123] 18/4/2020 11:56

This is for the less efficient method of administration, intravenously/subcutaneous...ofcourse we hold the invaluable and only patent for the faster and more efficient inhaled method!

Now why on earth would 70+ counties desperately want this interferon beta-1a?!

Boom times are very very close for Synairgen. The world is awaiting!!


From lse board...



rough translation 

As part of the global effort to investigate potential therapies for COVID-19 and our support for independent research, Merck is donating 290,000 units of its interferon beta-1a to the World Health Organization for use in the global SOLIDARITY trial, the which investigates various potential therapies for the treatment of COVID-19 and which, currently, has received expressions of interest from more than 70 countries. This action complements our previously announced donation for the international DISCOVERY trial, sponsored by the French institute INSERM (National Institute of Health and Medical Research).

To date, interferon beta-1a is not approved by any regulatory authority for the treatment of COVID-19 or for use as an antiviral agent.